<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04305197</url>
  </required_header>
  <id_info>
    <org_study_id>ICP-CL-00109</org_study_id>
    <nct_id>NCT04305197</nct_id>
  </id_info>
  <brief_title>A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)</brief_title>
  <official_title>A Phase Ib/IIa Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety, Tolerance, Pharmacokinetics/ Pharmacodynamics(PK/PD) of ICP-022 in Patients With Mild and Moderate Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing InnoCare Pharma Tech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing InnoCare Pharma Tech Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the Safety, Tolerability, PK/PD and preliminary
      Efficacy of ICP-022 in Subjects with Systemic Lupus Erythematosus (SLE)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2020</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants that experience Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 28 Days after the last dose of study drug</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients with Treatment-emergent Adverse Event(TEAEs) according to severity</measure>
    <time_frame>Up to 28 Days after the last dose of study drug</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant physical examination abnormalities</measure>
    <time_frame>Up to 28 Days after the last dose of study drug</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant vital signs abnormalities</measure>
    <time_frame>Up to 28 Days after the last dose of study drug</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant ECG abnormalities</measure>
    <time_frame>Up to 28 Days after the last dose of study drug</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant laboratory examination abnormalities</measure>
    <time_frame>Up to 28 Days after the last dose of study drug</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ratio of Patients With Response Based on Systemic Lupus Erythematosus Responder Index 4 (SRI-4)</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of Patients With Response Based on Systemic Lupus Erythematosus Responder Index 6 (SRI-6)</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occupancy rate of Bruton Tyrosine Kinase(BTK)</measure>
    <time_frame>14 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Immunoglobulin (Ig) level</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline in Ig levels</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline in C3</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline in C4</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline in serum dsDNA</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline in Anti-nuclear Antibodies</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline in Interferon-α(INF-α) level</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Changes from Baseline in cytokine levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline in Interleukin-6(IL-6) level</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Changes from Baseline in cytokine levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline in total B cell counts</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Beffs count</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Bregs count</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline in Bregs to Beffs ratio</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline in Erythrocyte Sedimentation Rate(ESR)</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The plasma concentration-time curve</measure>
    <time_frame>14 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Lower Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Higher Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ICP-022</intervention_name>
    <description>Tablet, 50mg, once a day, oral, will be administered for 12 weeks in double-blind treatment period</description>
    <arm_group_label>Lower Dose</arm_group_label>
    <other_name>Orelabrutinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ICP-022</intervention_name>
    <description>Tablet, 80mg, once a day, oral, will be administered for 12 weeks in double-blind treatment period</description>
    <arm_group_label>Medium Dose</arm_group_label>
    <other_name>Orelabrutinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ICP-022</intervention_name>
    <description>Tablet, 100mg, once a day, oral, will be administered for 12 weeks in double-blind treatment period</description>
    <arm_group_label>Higher Dose</arm_group_label>
    <other_name>Orelabrutinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Tablet, matched to ICP-022, once a day, oral, will be administered for 12 weeks in double-blind treatment period</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female subjects aged 18 to 75

          2. diagnosis of with SLE at least 6 months at screening visit

          3. Systemic lupus erythematosus disease activity index -2K (SLEDAE-2K) is ≥ 5

          4. Is receiving standard treatment for SLE and has been receiving treatment for at least
             3 months.

          5. Positive test result for anti-dsDNA and/or Antinuclear Antibody(ANA) and/or anti-Smith

          6. At least one SLE activity manifestation (as assessed by SLEDAE-2K) other than positive
             anti-dsDNA, and no Neuropsychiatric Systemic Lupus Erythematosus (NPSLE).

        Exclusion Criteria:

          1. Had been treated with a BTK inhibitor

          2. Neuropsychiatric lupus (NPSLE)

          3. Has other autoimmune diseases except SLE

          4. Plans to initiate or change anti-SLE therapy after screening visits

          5. Within 1 month prior to screening or during screening: use of corticosteroids greater
             than 25 mg daily dose of prednisone equivalent, or change in the dose of
             corticosteroids

          6. Within 1 week prior to screening or during screening: initiation or change dose of
             angiotensin converting enzyme inhibitors or angiotensin receptor blockers or
             Nonsteroidal Anti-inflammatory Drugs (NSAID)

          7. Within 3 months before or during screening: initiation or change in dose of
             methotrexate, mycophenolic acid (mycophenolate or sodium mycophenolate), or
             azathioprine, hydroxychloroquine sulfate,

          8. Within 3 months prior to or during screening: use of cyclosporine, tacrolimus,
             leflunomide, abatacept, iv immunoglobulin, plasma exchange, or other
             immunosuppressants

          9. Within 6 months prior to or during screening: use of cyclophosphamide, chlorambucil,
             rituximab, belimumab, or any other treatment that depletes or regulates B cells

         10. Within 1 month before or during screening: live virus vaccine or attenuated virus
             vaccine

         11. The presence of an active and uncontrolled infection

         12. Creatinine clearance ≤30 ml/min [estimated by Cockcroft-Gault formula]

         13. 24-hour Urine protein &gt; 6 g/d
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhanguo Li, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhanguo Li, MD/PhD</last_name>
    <phone>010-88324172</phone>
    <email>Zgli@yahoo.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhanguo Li, MD/PhD</last_name>
      <phone>010-8832</phone>
      <phone_ext>4172</phone_ext>
      <email>Zgli@yahoo.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University third hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinxia Zhao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gulou Hospital Affiliated to Medical College of Nanjing University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lingyun Sun</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 10, 2020</study_first_submitted>
  <study_first_submitted_qc>March 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2020</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mild to Moderate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

